Conditioning with melphalan 200 mg/m(2) and subsequent ASCT improves progression-free and overall survival in elderly myeloma patients compared to standard of care

Afram, G; Chaireti, R; Uttervall, K; Luong, V; Lund, J; Kashif, M; Gahrton, G; Alici, E; Nahi, H

Chaireti, R (通讯作者),Karolinska Inst, Dept Mol Med & Surg, S-17177 Stockholm, Sweden.

EUROPEAN JOURNAL OF HAEMATOLOGY, 2022; 109 (6): 749

Abstract

Objectives Despite the effectiveness of newer drugs for the treatment of multiple myeloma (MM), the outcomes are further improved by subsequent autolo......

Full Text Link